Soft Tissue Repair Market Scope And Analysis

Report Code : TIPHE100000830
Category : Life Sciences

Status : Published
No. of Pages : 183

Buy Now

Soft Tissue Repair Market Scope and Analysis by 2025

Buy Now

Soft Tissue Repair Market Report Scope

Report Attribute	Details
Market size in 2019	US$ 4.08 Billion
Market Size by 2025	US$ 6.68 Billion
Global CAGR (2019 - 2025)	8.3%
Historical Data	2017-2018
Forecast period	2020-2025
Segments Covered	By Product Fixation Instruments and Tissue Mesh By Application Orthopedic Repair Hernia Repair Breast Reconstruction Skin Repair Pelvic and Vaginal Prolapse Repair Dental and Dural Repair
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Smith Nephew DePuy Synthes Arthrex Inc Medtronic Integra Lifesciences Corporation Stryker Corporation BD Organogenesis Inc Allergan Plc

Recent Developments

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the soft tissue repair market. A few recent key market developments are listed below:

In January 2023, Arthrex’s ACL TightRope implant received clearance from the US Food and Drug Administration (FDA) for pediatric indications. The TightRope implant is used in the surgical treatment of orthopedic injuries and is the first and only fixation device for ACL injuries cleared for pediatric use.
In August 2022, CONMED Corporation completed the acquisition of privately held Biorez, Inc (a medical device start-up focused on advancing the healing of soft tissue using its proprietary BioBrace Implant technology). The BioBrace Implant is an innovative bio-inductive scaffold intended to reinforce soft tissue and facilitate healing. The acquisition was settled on cash consideration of US$85 million at closing and up to an additional US$165 million in growth-based earnout payments over four years.
In September 2021, Stryker’s Trauma & Extremities division launched its Citrelock Tendon Fixation Device System to provide surgeons with a differentiated design via a tendon thread featuring a resorbable technology called Citregen.
In July 2021, BD acquired Tepha, Inc., a leading developer and manufacturer of proprietary resorbable polymer technology. Tepha's Poly 4-hydroxybutyric acid, P4HB technology platform provides additional innovation potential that accelerates the growth of BD's surgical mesh portfolio and drives the company into potential new areas within soft tissue repair, reconstruction, and regeneration.